新发风湿性多肌痛患者报告结局指标:治疗后变化、短期停用糖皮质激素及一年随访
该前瞻性队列纳入60例新发风湿性多肌痛(PMR)患者,在基线、第8周、短期停用糖皮质激素后第10周及诊断后一年评估患者报告结局指标(PROMs)。所有PROMs从基线至第8周改善(p<0.001),停用激素后除SF-36心理成分外均恶化,一年时疼痛VAS和PMR VAS高于第8周;第10周复发者第8和10周VAS更高、SF-36生理子量表更低。
要点
- PMR患者启动糖皮质激素后8周内PROMs显著改善,VAS平均下降59mm。
- 短期停用糖皮质激素后除SF-36心理成分外PROMs均恶化,提示监测PROMs有助于发现复发。
- 医师整体评估(PhGA)与PMR VAS、肩痛及整体疼痛强相关(r>0.75,p<0.01)。
核心结论
- PROMs尤其是疼痛相关VAS评分可能预测PMR复发并指导个体化减量策略。
- PhGA与PROMs强相关,支持将PROMs整合入常规监测。
研究设计与样本
- 前瞻性队列研究,从丹麦三个风湿科招募疑似PMR患者,共纳入60例无合并或晚发巨细胞动脉炎的PMR患者。
- 患者在基线、第8周、短期停用糖皮质激素后第10周及诊断后一年接受临床评估、实验室检查和PROMs。
主要发现
- 所有PROMs从基线至第8周改善(p<0.001),VAS评分平均下降59mm。
- 从第8周至第10周,除SF-36心理成分评分外所有PROMs恶化(p<0.01)。
- 一年时疼痛VAS和PMR VAS高于第8周(p<0.01)。
- 第10周复发患者在第8周和第10周的VAS评分更高、SF-36生理子量表评分更低(p<0.05)。
- PhGA与PMR VAS、肩痛和整体疼痛强相关(r>0.75,p<0.01)。
临床怎么用
- 在PMR常规监测中整合PROMs,尤其疼痛VAS,可能有助于识别复发风险并指导个体化糖皮质激素减量。
局限性
- 样本量较小(60例),仅来自丹麦三个风湿科,结论外推需谨慎。
- 原文未报告PROMs预测复发的阈值或剂量调整方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The role of patient-reported outcomes measures (PROMs) in polymyalgia rheumatica (PMR) remains scarcely studied. This study evaluated PROMs at baseline, after glucocorticoid (GC) initiation, following short-term GC discontinuation, and one year after diagnosis in patients with PMR. METHODS: A prospective cohort of patients suspected of PMR was enrolled from three Danish rheumatology departments. Patients with PMR initiated GC treatment. Clinical assessment, including physicians' global assessment of disease activity (PhGA), laboratory tests, and PROMs, were performed at baseline, week 8, week 10 after short-term GC discontinuation, and after one year. PROMs comprised different pain visual analogue scales (VAS), PMR VAS, morning stiffness duration, and 36-item Short-Form Survey (SF-36). RESULTS: A total of 60 patients with PMR, without concomitant or late-onset giant cell arteritis, were included. All PROMs improved from baseline to week 8 (p < 0.001), with an average decrease of 59 mm in VAS scores. From week 8 to 10, all PROMs except the SF-36 mental component score worsened (p < 0.01). Pain VAS and PMR VAS were higher after one year than at week 8 (p < 0.01). Patients with relapse at week 10 had higher VAS scores and lower SF-36 physical subscale scores at week 8 and 10 (p < 0.05) compared with patients without relapse. PhGA correlated strongly with PMR VAS, shoulder pain, and global pain (r > 0.75, p < 0.01). CONCLUSION: PROMs, particularly pain-related VAS scores, may predict relapse and guide individualised tapering strategies in patients with PMR. The strong correlations between PhGA and PROMs highlight the clinical relevance of integrating PROMs into routine monitoring.
引用
- Bjerre AB, Nielsen AW, Våben CS, et al. Patient-reported outcome measures in incident Polymyalgia Rheumatica: Changes after treatment initiation, short-term glucocorticoid discontinuation, and at one-year follow-up. Semin Arthritis Rheum. 2026. PMID: 42025129. doi:10.1016/j.semarthrit.2026.152982
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。